Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...
Market launch
Merck Launches Noxafil in China for Antifungal Treatment
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced the official market launch...
Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...
AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
Livzon Launches National Rollout of COVID-19 Vaccine V-01 in China
China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel...
Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...
Boston Scientific Launches Disposable RF Electrode for Chronic Pain in China
Boston Scientific Corporation (NYSE: BSX), a US-based medical device company, has announced the official market...
Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...
Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center
US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...
HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy
China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...
Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...
CanSino Biologics Launches Menhycia Meningococcal Vaccine in Six Provinces
China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197)...
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China
Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...
Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...
Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China
China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...